Prescription performance of compound drugs has increased significantly in the market for diabetic drugs in the SGLT-2 inhibitors. Outpatient Rx increased by 23% in the second quarter of the year. The single formulation only increased by 4% during the same period, showing slowing down.

According to UBIST, a pharmaceutical market research agency on the 23rd, the total amount of outpatient prescriptions for diabetes treatments related to SGLT-2 inhibitors in the second quarter is estimated at ₩32.2 billion. Compared to ₩29.2 billion in the second quarter of last year, it increased by 10%.

Market growth was led by combination formulations. The combined prescriptions for X